---
title: "Kepler Capital  Sticks to Its Buy Rating for DBV Technologies (0QAJ)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280897149.md"
description: "Kepler Capital analyst Justine Telliez has maintained a Buy rating on DBV Technologies (0QAJ) as of March 27, with a price target of €5.50. The shares closed at €3.54 last Friday. Telliez, a top 100 analyst with a 64.9% average return, focuses on the Healthcare sector. The current analyst consensus for DBV Technologies is a Moderate Buy, also with an average price target of €5.50."
datetime: "2026-03-29T05:29:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280897149.md)
  - [en](https://longbridge.com/en/news/280897149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280897149.md)
---

# Kepler Capital  Sticks to Its Buy Rating for DBV Technologies (0QAJ)

Kepler Capital analyst Justine Telliez maintained a Buy rating on DBV Technologies on March 27 and set a price target of €5.50. The company’s shares closed last Friday at €3.54.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Telliez is a top 100 analyst with an average return of 64.9% and a 58.91% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Valneva, Genfit, and DBV Technologies.

Currently, the analyst consensus on DBV Technologies is a Moderate Buy with an average price target of €5.50.

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [DBVT.US](https://longbridge.com/en/quote/DBVT.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)](https://longbridge.com/en/news/286443716.md)